145O - Prognostic role for derived neutrophil-to-lymphocyte ratio in early breast cancer

Date 07 October 2016
Event ESMO 2016 Congress
Session Breast cancer, early
Topics Breast Cancer, Early Stage
Presenter Alberto Ocana Fernandez
Citation Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364
Authors A. Ocana Fernandez1, A.J. Templeton2, M. Casas3, M. Sánchez-Aragó4, R. Caballero3, A. Rodríguez Lescure5, A. Ruiz6, E. Alba7, L. Calvo8, M. Ruiz9, A. Santaballa10, C. Rodríguez11, C. Crespo12, M. Ramos13, J.M. Gracia Marco14, A. Lluch-Hernandez15, I. Alvarez16, E. Carrasco3, E. Amir17, M. Martin18
  • 1Research Unit And Medical Oncology, Albacete University Hospital, 02006 - Albacete/ES
  • 2Klinik Für Onkologie, St. Claraspital, 4058 - Basel/CH
  • 3GEICAM (Spanish Breast Cancer Research Group), Madrid/ES
  • 4Translational Research, GEICAM (Spanish Breast Cancer Research Group), Madrid/ES
  • 5Medical Oncology, Hospital General Universitario de Elche, Alicante/ES
  • 6Medical Oncology, Fundación Instituto Valenciano de Oncología, 46008 - Valencia/ES
  • 7Hospital Universitario Regional Y Virgen De La Victoria, Instituto de Investigacion Biomedica de Malaga (IBIMA), 29010 - Malaga/ES
  • 8Medical Oncology, 7Complejo Hospitalario Juan Canalejo, A Coruna/ES
  • 9Medical Oncology, Hospital Universitario Virgen del Rocio, Sevilla/ES
  • 10Medical Oncology, Hospital Universitari i Politècnic La Fe, 46026 - Valencia/ES
  • 11Medical Oncology, Clínico de Salamanca Hospital, Salamanca/ES
  • 12Medical Oncology, Hospital Universitario Ramon y Cajal, Madrid/ES
  • 13Medical Oncology, Centro Oncologico de Galicia, A Coruna/ES
  • 14Medical Oncology, Hospital de Cabueñes, Gijon/ES
  • 15Serv. Hematologia Y Oncologia Medica, Hospital Clinico Universitario de Valencia, 46010 - Valencia/ES
  • 16Medical Oncology Dept., Hospital Donostia, 20080 - San Sebastian/ES
  • 17Medical Oncology, Princess Margaret Hospital, M5G 2M9 - Toronto/CA
  • 18Medical Oncology, Canada17Instituto de Investigación Sanitaria Gregorio Marañón, Madrid/ES



Inflammation is a hallmark of cancer. Elevated markers of host inflammation have been associated with worse outcomes in several solid tumors. Here, we explore the prognostic role of the derived neutrophil-to-lymphocyte ratio (dNLR) in subgroups of women with early breast cancer.


This was a retrospective analysis of women with early breast cancer included in the GEICAM/9906 trial, a randomized phase III study of adjuvant FEC compared to FEC-paclitaxel (FEC-P) in breast cancer patients with axillary involvement. dNLR was calculated as the ratio of neutrophils divided by the difference between total leukocytes and neutrophils measured in peripheral blood before the start of chemotherapy. The primary objective was disease free survival (DFS) and overall survival (OS) was a secondary endpoint. Univariable Cox regression was used to explore the prognostic and predictive value of dNLR (explored as median cutoff and grouped in quartiles). Subgroups by PAM50 subtype and hormonal receptor expression were subsequently analyzed.


The current analysis comprised 1243 patients from 65 Spanish sites with a median follow-up of 10 years. Median age was 50 years (range 23-76), 66% of patients had available PAM50 subtype determination, of which 22% of the tumors were Luminal A, 21% Luminal B, 14% Her2-enriched, 6% Basal-like, and 3% Normal-like. ER+/PgR+ and ER/PgR subtypes comprised 47% and 13% of evaluable tumors, respectively. Median dNLR was 1.35 (IQR 1.08 – 1.71). For Her2-enriched patients by PAM50, a dNLR > median was significantly associated with worse DFS, p = 0.03 (HR: 1.63; 95%CI: 1.04 – 2.54). For non-luminal patients by PAM50, a dNLR > median and a high dNLR explored by quartiles were associated with worse DFS (p = 0.02 and p = 0.03, respectively). For patients with ER/PgR tumors, a high dNLR grouped in quartiles was associated with worse DFS and OS (p 


dNLR is associated with worse DFS in women with Her2-enriched and non-luminal intrinsic subtypes defined by PAM50 multigene expression assay. High dNLR is also associated with worse DFS and OS in women with ER-/PgR- tumors (IHC). Further studies are warranted to confirm these findings.

Clinical trial identification

Nº EudraCT: 2005-003108-12

Legal entity responsible for the study

GEICAM Spanish Breast Cancer Group


GEICAM Spanish Breast Cancer Group


All authors have declared no conflicts of interest.